Anbogen Therapeutics

Executive Summary

Anbogen Therapeutics is a Taiwan-based precision oncology company leveraging an AI-driven drug discovery platform to develop targeted cancer therapies. Founded in 2020, the company has advanced its lead candidate, ABT-301, into Phase 1 clinical trials for advanced colorectal cancer. ABT-301 is a novel combination regimen designed to overcome resistance mechanisms and improve patient outcomes. The company's platform integrates computational design with clinical development, enabling efficient identification of synergistic drug pairs. While still in early clinical stages, Anbogen's approach targets a significant unmet need in colorectal cancer, a major cause of cancer mortality worldwide. The company is privately held and has not disclosed funding or valuation details.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data readout for ABT-301 in advanced colorectal cancer45% success
• Q2 2027FDA IND clearance for a second pipeline candidate55% success
• TBDStrategic partnership or licensing deal for ABT-30130% success